Pterostilbene vs Resveratrol 2026: Which Polyphenol Is Worth It?
Pterostilbene vs Resveratrol 2026: Which Polyphenol Is Worth It?
Resveratrol became famous after epidemiologists noticed that the French — despite a diet rich in saturated fat — had comparatively lower cardiovascular disease rates. Researchers pointed to red wine polyphenols, and resveratrol became one of the most-hyped longevity supplements of the 2000s.
Pterostilbene, resveratrol's lesser-known cousin, emerged later with a structural advantage: two methoxy groups (replacing hydroxyl groups) make it dramatically more bioavailable. The question for the informed supplement buyer is: does better bioavailability translate into better outcomes, and for which specific health goals?
This evidence-based comparison gives you the honest answer — including the important caveat most pterostilbene advocates skip.
How We Score
We evaluate each product using the G6 5-factor composite scoring system:
| Factor | Weight | What We Measure | |--------|--------|-----------------| | Evidence Quality | 30% | RCT support, effect sizes, study quality, replication | | Ingredient Transparency | 25% | Full disclosure, clinical doses, no proprietary blends | | Value | 20% | Cost per serving vs. competing products | | Real-World Performance | 15% | Verified-purchase reviews, user-reported outcomes | | Third-Party Verification | 10% | NSF, USP, Informed Sport, or equivalent certification |
The Science: How They Compare
Molecular Structure and Bioavailability
Both pterostilbene and resveratrol are stilbene polyphenols. Their molecular structures differ in one key location: resveratrol has three hydroxyl (-OH) groups; pterostilbene replaces two of those with methoxy (-OCH₃) groups.
This single structural change has dramatic pharmacokinetic consequences. A rat pharmacokinetic study found pterostilbene had approximately 80% oral bioavailability compared to approximately 20% for resveratrol. Peak plasma concentration (Cmax) was 36× higher for pterostilbene at equivalent doses, with a half-life of 105 minutes vs. 14 minutes for resveratrol (Kapetanovic IM et al., 2011, PMID: 21116625).
The reason: methoxy groups increase lipophilicity, reducing rapid Phase II glucuronide/sulfate conjugation in the gut and liver — the primary mechanism by which resveratrol is rapidly metabolized before reaching circulation.
Clinical implication: A 50 mg dose of pterostilbene may deliver more bioactive compound to target tissues than a 500 mg dose of standard resveratrol. However, pharmacokinetic superiority in animals does not automatically translate to superior clinical outcomes in humans.
Mechanisms of Action
Both compounds activate overlapping but distinct pathways:
| Pathway | Pterostilbene | Resveratrol | |---------|--------------|-------------| | SIRT1 activation | Moderate | Strong (primary mechanism) | | PPAR-alpha activation | Strong (key differentiator) | Minimal | | AMPK activation | Yes | Yes | | NF-κB inhibition | Yes | Yes | | Nrf2/antioxidant response | Yes | Yes | | eNOS upregulation | Moderate | Strong | | Estrogen receptor modulation | Minimal | Yes (phytoestrogen-like) | | BBB penetration | Superior (lipophilicity) | Limited |
Pterostilbene's PPAR-alpha activation is its key functional differentiator — driving neuroprotective effects, lipid oxidation, and anti-inflammatory activity through a pathway resveratrol does not meaningfully engage. PPAR-alpha is highly expressed in the liver, heart, and brain.
Resveratrol's stronger SIRT1 activation and eNOS upregulation explain its cardiovascular and anti-aging signaling profile. Its phytoestrogen-like estrogen receptor modulation likely explains the cognitive benefit seen specifically in postmenopausal women (Thaung Zaw JJ et al., 2021, PMID: 32900519).
The Evidence by Use Case
Cognition and Brain Health
Resveratrol human evidence (strong): A 24-month double-blind, crossover RCT in 125 postmenopausal women (ages 45–85) using 75 mg twice daily (150 mg/day trans-resveratrol) showed a 33% improvement in overall cognitive performance vs. placebo. Cerebral blood flow velocity, cerebrovascular responsiveness, and insulin sensitivity also improved. Women aged 65+ showed greater verbal memory benefit (Thaung Zaw JJ et al., 2021, PMID: 32900519).
A systematic review and meta-analysis of resveratrol RCTs confirmed modest but consistent cognitive benefits, particularly in older adults and those with metabolic risk factors (Marx W et al., 2018, PMID: 29596658).
Pterostilbene animal evidence (promising): In SAMP8 accelerated-aging mice (a validated sporadic Alzheimer's model), low-dose pterostilbene significantly improved maze performance while resveratrol showed no significant benefit. Pterostilbene, but not resveratrol, upregulated PPAR-alpha and modulated markers of cellular stress and Alzheimer's pathology (Chang J et al., 2012, PMID: 21982274). Superior BBB penetration drives this advantage.
Verdict: Resveratrol wins on human cognition evidence. Pterostilbene's animal neuroprotection data is compelling but not yet matched by human RCTs.
Blood Sugar and Metabolic Control
Resveratrol (strong human evidence): A meta-analysis of 11 RCTs (388 participants) found resveratrol significantly reduced fasting glucose, insulin, HbA1c, and insulin resistance (HOMA-IR) in diabetic patients. Importantly, no significant effect was seen in non-diabetic participants (Liu K et al., 2014, PMID: 24695890). A 2022 RCT (200 mg/day, 24 weeks, 94 T2DM patients) confirmed reductions in glucose, insulin, and HOMA-IR alongside decreased pro-inflammatory cytokines TNF-α, IL-6, and CRP (Mahjabeen W et al., 2022, PMID: 35240291).
Pterostilbene: No dedicated human T2DM blood glucose RCTs. AMPK activation is mechanistically shared with resveratrol, but clinical data is absent for this specific indication.
Verdict: Resveratrol wins for blood sugar support — multiple RCTs in diabetic populations.
Cholesterol and Lipids
Resveratrol (positive): A dose-response meta-analysis of RCTs found significant reductions in total cholesterol (−10.28 mg/dL), triglycerides (−8.56 mg/dL), and LDL (−5.69 mg/dL). Effects were larger in T2DM patients and trials ≥12 weeks (Cao X et al., 2022, PMID: 36145131).
Pterostilbene (important caveat): A human RCT found pterostilbene monotherapy at 250 mg/day raised LDL cholesterol by +17.1 mg/dL (p=0.001) in hypercholesterolemic adults. Blood pressure improved (systolic −7.8 mmHg, diastolic −7.3 mmHg), but the LDL increase is a meaningful concern for cardiovascular-risk individuals. This LDL effect was attenuated when pterostilbene was combined with grape extract (Riche DM et al., 2014, PMID: 25057276).
Verdict: Resveratrol wins for lipid management. Pterostilbene monotherapy may worsen LDL — use with caution in cardiovascular-risk individuals; combine with resveratrol or grape polyphenols if using pterostilbene.
Blood Pressure
Pterostilbene: The same RCT that showed LDL elevation also showed significant blood pressure reduction: systolic −7.8 mmHg, diastolic −7.3 mmHg at 250 mg/day (Riche DM et al., 2014, PMID: 25057276). This is a meaningful effect for hypertensive patients.
Resveratrol: eNOS upregulation is well-documented mechanistically, but human BP trials are inconsistent.
Verdict: Pterostilbene has a more reliable blood pressure signal in human data.
Liver Health
Pterostilbene + NR combination: A 6-month double-blind RCT in 111 NAFLD adults using Nicotinamide Riboside + Pterostilbene (NRPT) significantly reduced liver enzymes ALT and GGT vs. placebo, and reduced the toxic lipid ceramide 14:0 (Dellinger RW et al., 2023, PMID: 36082508). Pterostilbene was not studied in isolation; combination effects cannot be attributed solely to pterostilbene.
Longevity Pathways
Both compounds activate the core longevity signaling network: SIRT1/2, AMPK, Nrf2, and NF-κB modulation. Pterostilbene adds PPAR-alpha; resveratrol adds stronger eNOS activity. A comparative review concluded both are credible longevity compounds through overlapping and complementary mechanisms, with neither having human lifespan data (Li YR et al., 2018, PMID: 29210129).
Head-to-Head Summary
| Use Case | Winner | Evidence Level | |----------|--------|---------------| | Bioavailability | Pterostilbene | Strong (animal PK) | | Cognitive function (human data) | Resveratrol | Strong RCT (PMID: 32900519) | | Blood sugar management (T2DM) | Resveratrol | Strong meta-analysis (PMID: 24695890) | | Cholesterol reduction | Resveratrol | Meta-analysis (PMID: 36145131) | | Blood pressure reduction | Pterostilbene | RCT (PMID: 25057276) | | Neuroprotection (animal models) | Pterostilbene | Animal RCT (PMID: 21982274) | | Liver health (NAFLD, with NR) | Pterostilbene + NR | Moderate RCT (PMID: 36082508) | | LDL safety concern | Resveratrol safer | Pterostilbene raised LDL (PMID: 25057276) | | Human clinical trial volume | Resveratrol | Decisively more trials |
Top Pterostilbene Supplements
1. Double Wood Supplements Pterostilbene 100 mg — Best Overall Pterostilbene
Price: ~$22–28 / 60 capsules (~$0.37–0.47/capsule) Dose: 100 mg pterostilbene per capsule
Double Wood is one of the most transparent supplement companies in the nootropic space — all products come with a Certificate of Analysis, made in FDA-registered US facilities. Their 100 mg pterostilbene capsule is a clean, single-ingredient product at the dose used in the lower end of the key RCT range (100–250 mg/day from Riche DM et al., 2013, PMID: 23431291).
G6 Score Breakdown:
| Criterion | Weight | Score | Weighted | |-----------|--------|-------|---------| | Evidence Quality | 30% | 7.0 | 2.10 | | Ingredient Transparency | 25% | 8.5 | 2.13 | | Value | 20% | 7.0 | 1.40 | | Real-World Performance | 15% | 7.5 | 1.13 | | Third-Party Verification | 10% | 7.0 | 0.70 | | Composite | | | 7.5 |
Score notes: Double Wood's COA-on-request policy and FDA-registered facility earn high transparency marks. Evidence score reflects the compound category (not yet matched with resveratrol's human RCT volume). Third-party verification strong for a small-batch nootropic brand.
→ Check Double Wood Pterostilbene on Amazon
2. Jarrow Formulas trans-Pterostilbene 50 mg — Best Low-Dose Entry
Price: ~$20–26 / 60 vegetarian capsules (~$0.33–0.43/capsule) Dose: 50 mg trans-pterostilbene per capsule
Jarrow Formulas is a well-established, quality-focused brand with decades of supplement formulation experience. Their 50 mg dose is suitable for individuals starting pterostilbene supplementation or combining with resveratrol. Specifies trans-pterostilbene (the biologically active form), which is the appropriate isomer to seek.
G6 Score Breakdown:
| Criterion | Weight | Score | Weighted | |-----------|--------|-------|---------| | Evidence Quality | 30% | 6.5 | 1.95 | | Ingredient Transparency | 25% | 8.0 | 2.00 | | Value | 20% | 7.0 | 1.40 | | Real-World Performance | 15% | 7.0 | 1.05 | | Third-Party Verification | 10% | 6.5 | 0.65 | | Composite | | | 7.1 |
Score notes: Jarrow's established brand reputation and form specificity (trans-pterostilbene) earn strong transparency marks. Evidence score slightly lower due to the 50 mg dose being below the key human trial range (100–250 mg/day). Good for stacking with resveratrol.
→ Check Jarrow trans-Pterostilbene on Amazon
Top Resveratrol Supplements
1. Toniiq Ultra High Purity Resveratrol — Best Overall Resveratrol
Price: ~$28–35 / 60 capsules (~$0.47–0.58/capsule) Dose: 600 mg per capsule (98%+ purity trans-resveratrol)
Toniiq specializes in ultra-high-purity compounds verified by independent third-party testing. Their 98%+ trans-resveratrol is the highest purity available in a commercial supplement — important because lower-purity products often contain significant amounts of the inactive cis-resveratrol isomer. A 600 mg dose is at the high end of what human trials have used (Liu K et al., 2014, PMID: 24695890 used 100–500 mg/day range).
Label Analysis: Single ingredient, 98%+ trans-resveratrol, third-party COA available on website. No proprietary blend. Vegetarian capsule.
G6 Score Breakdown:
| Criterion | Weight | Score | Weighted | |-----------|--------|-------|---------| | Evidence Quality | 30% | 8.0 | 2.40 | | Ingredient Transparency | 25% | 9.0 | 2.25 | | Value | 20% | 6.5 | 1.30 | | Real-World Performance | 15% | 7.5 | 1.13 | | Third-Party Verification | 10% | 8.0 | 0.80 | | Composite | | | 7.9 |
Score notes: Highest scores in this roundup on evidence quality (strong resveratrol human RCT base) and transparency (98%+ purity, third-party COA). Value is moderate — premium purity justifies the price premium but 60-cap count limits bulk value.
→ Check Toniiq Ultra Purity Resveratrol on Amazon
2. Life Extension Optimized Resveratrol Elite — Best Full-Spectrum
Price: ~$25–32 / 60 capsules (~$0.42–0.53/capsule) Dose: Trans-resveratrol + quercetin + fisetin combination
Life Extension's Optimized Resveratrol Elite takes a synergistic formulation approach: resveratrol with quercetin (a flavonoid that shares SIRT1-activating and anti-inflammatory pathways) and fisetin (a senolytic flavonoid). The combination addresses multiple polyphenol pathways simultaneously.
Note: The multi-ingredient format reduces per-ingredient dose vs. a pure resveratrol product at the same price. Appropriate for readers wanting broader polyphenol coverage over maximum resveratrol dose.
G6 Score Breakdown:
| Criterion | Weight | Score | Weighted | |-----------|--------|-------|---------| | Evidence Quality | 30% | 7.5 | 2.25 | | Ingredient Transparency | 25% | 7.5 | 1.88 | | Value | 20% | 7.0 | 1.40 | | Real-World Performance | 15% | 7.5 | 1.13 | | Third-Party Verification | 10% | 7.5 | 0.75 | | Composite | | | 7.4 |
Score notes: Life Extension is a highly reputable brand with strong quality standards. Evidence score reflects the combination formula (each component has human trial data). Transparency slightly lower than single-ingredient options due to multi-component dosing complexity.
→ Check Life Extension Optimized Resveratrol on Amazon
3. Doctor's Best Trans-Resveratrol 600 mg — Best Value Resveratrol
Price: ~$20–26 / 60 capsules (~$0.33–0.43/capsule) Dose: 600 mg trans-resveratrol (from Polygonum cuspidatum root extract)
Doctor's Best delivers a clean 600 mg trans-resveratrol at a competitive price point. Polygonum cuspidatum (Japanese knotweed) is the standard commercial source for trans-resveratrol and the same source used in most human trials. Non-GMO, vegetarian, and gluten-free.
G6 Score Breakdown:
| Criterion | Weight | Score | Weighted | |-----------|--------|-------|---------| | Evidence Quality | 30% | 7.5 | 2.25 | | Ingredient Transparency | 25% | 8.0 | 2.00 | | Value | 20% | 8.0 | 1.60 | | Real-World Performance | 15% | 7.0 | 1.05 | | Third-Party Verification | 10% | 6.5 | 0.65 | | Composite | | | 7.6 |
Score notes: Best value among resveratrol picks — lower per-capsule cost with clinical 600 mg dose. Evidence score reflects the strong resveratrol human RCT base. Third-party verification moderate (no NSF/USP — common for this tier).
→ Check Doctor's Best Trans-Resveratrol on Amazon
Who Should Choose What
Choose Pterostilbene if:
- Your primary goal is neuroprotection or brain health — pterostilbene's PPAR-alpha activation and BBB penetration give it mechanistic advantages; human cognition data is pending but animal evidence is compelling
- You want to address blood pressure — the human RCT showed a meaningful reduction (-7.8/-7.3 mmHg)
- You've previously had poor response to resveratrol — higher bioavailability may explain variable responder patterns
- You are combining it with resveratrol or grape polyphenols — the combination attenuates the LDL-raising effect and provides broader pathway coverage
Choose Resveratrol if:
- You want the most human RCT-backed polyphenol — resveratrol has vastly more human trial data
- Blood sugar management in diabetes is a priority — multiple RCTs show benefit in T2DM
- Cholesterol management is a goal — meta-analysis data shows TC, TG, and LDL reductions
- You have cardiovascular risk factors — avoid pterostilbene monotherapy due to LDL elevation risk
- Cognitive health is the goal and you want human-backed evidence — the 24-month postmenopausal women RCT is the best polyphenol cognition trial published to date
Consider Both Together:
The most sophisticated approach uses both compounds. Pterostilbene's PPAR-alpha activation + superior bioavailability complements resveratrol's SIRT1 activation and stronger glucose/lipid human data. The pterostilbene LDL concern is attenuated in combination. Several commercial products combine them (e.g., Elysium Basis contains NR + pterostilbene; other products combine pterostilbene + trans-resveratrol directly).
Safety Considerations
Pterostilbene safety flags:
- Raises LDL cholesterol in monotherapy at 250 mg/day — caution in cardiovascular-risk patients
- Three cases of myopathy in a safety trial (non-statin users); monitor muscle symptoms
- Long-term human safety data beyond 8 weeks is not available
Resveratrol safety flags:
- Above 1,000 mg/day: GI side effects (nausea, diarrhea) common; elevated liver enzymes (reversible) possible
- CYP3A4/2C9/2D6 inhibition at high doses — interactions with statins, warfarin, calcium channel blockers
- Anti-platelet activity — increased bleeding risk with anticoagulants
- Pro-estrogenic effects — caution in hormone-sensitive conditions (ER+ breast cancer)
Frequently Asked Questions
What is the main difference between pterostilbene and resveratrol?
Both are stilbene polyphenols found in plants (blueberries, grapes), but pterostilbene has two methoxy groups where resveratrol has hydroxyl groups. This makes pterostilbene ~4× more lipophilic, giving it dramatically better oral bioavailability (~80% vs. ~20%), a longer half-life (105 min vs. 14 min), and superior blood-brain barrier penetration. Resveratrol has a larger human RCT evidence base. Pterostilbene has better pharmacokinetics but fewer human trials.
Which is better for brain health — pterostilbene or resveratrol?
For cognitive benefits in humans, resveratrol has stronger direct evidence: a 24-month RCT in postmenopausal women (150 mg/day) showed a 33% improvement in overall cognitive performance vs. placebo (Thaung Zaw JJ et al., 2021, PMID: 32900519). Pterostilbene shows superior neuroprotection in animal aging models via PPAR-alpha activation and better BBB penetration (Chang J et al., 2012, PMID: 21982274), but lacks equivalent human cognition RCTs.
Does pterostilbene raise LDL cholesterol?
Yes — this is an important caveat. A human RCT found pterostilbene at 250 mg/day raised LDL cholesterol by +17.1 mg/dL in hypercholesterolemic patients (Riche DM et al., 2014, PMID: 25057276). This effect was attenuated when pterostilbene was combined with grape polyphenols. Resveratrol, by contrast, is associated with LDL reduction. Patients with existing cardiovascular risk should discuss pterostilbene with their healthcare provider.
What dose of pterostilbene is effective?
Human trials have studied 50–250 mg/day split into twice-daily doses. Safety was confirmed up to 250 mg/day for 6–8 weeks (Riche DM et al., 2013, PMID: 23431291). For general antioxidant/longevity use, 50–100 mg/day is typical. For blood pressure or metabolic effects, 100–250 mg/day was used in the key RCT. Pterostilbene is fat-soluble — take with a meal containing dietary fat.
Can you take pterostilbene and resveratrol together?
Yes — combining them is a common formulation strategy. Pterostilbene activates PPAR-alpha and has better bioavailability; resveratrol activates SIRT1 more potently and has stronger human evidence for blood sugar and lipid effects. Together they offer broader pathway coverage. The LDL-raising effect of pterostilbene monotherapy was attenuated in the grape polyphenol combination study. Combination products are available at most doses.
Final Verdict
For resveratrol: Toniiq Ultra High Purity Resveratrol (G6: 7.9) is the best choice — 98%+ purity trans-resveratrol with third-party verification. Doctor's Best Trans-Resveratrol (G6: 7.6) is the value pick.
For pterostilbene: Double Wood Supplements (G6: 7.5) is the best standalone pick with COA transparency and a clinically relevant 100 mg dose.
The informed choice: Unless you have a compelling reason to use pterostilbene specifically (blood pressure, neuroprotection, resveratrol non-response), resveratrol has the stronger human clinical case for the two most common goals — blood sugar management and cognitive support. If cardiovascular risk is a factor, avoid pterostilbene monotherapy.
Research supported by 13 peer-reviewed studies. Full citations in research file. Last reviewed: March 2026.